DE60228717D1 - Eine pharmazeutische kolloidale Zusammensetzung enthaltend Hyaluronsäure-Biopolymere zur Behandlung von Atemwegserkrankungen - Google Patents

Eine pharmazeutische kolloidale Zusammensetzung enthaltend Hyaluronsäure-Biopolymere zur Behandlung von Atemwegserkrankungen

Info

Publication number
DE60228717D1
DE60228717D1 DE60228717T DE60228717T DE60228717D1 DE 60228717 D1 DE60228717 D1 DE 60228717D1 DE 60228717 T DE60228717 T DE 60228717T DE 60228717 T DE60228717 T DE 60228717T DE 60228717 D1 DE60228717 D1 DE 60228717D1
Authority
DE
Germany
Prior art keywords
hyaluronic acid
composition
treatment
mixture
colloidal composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60228717T
Other languages
English (en)
Inventor
Giuseppe Petrigni
Luigi Allegra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atlas 2002 Cherry Hill Nj Us LLC
Flostock Cherry Hill Nj Us LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60228717D1 publication Critical patent/DE60228717D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60228717T 2002-10-10 2002-10-11 Eine pharmazeutische kolloidale Zusammensetzung enthaltend Hyaluronsäure-Biopolymere zur Behandlung von Atemwegserkrankungen Expired - Lifetime DE60228717D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/267,863 US7060691B2 (en) 2002-10-10 2002-10-10 Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
EP02022717A EP1407776B1 (de) 2002-10-10 2002-10-11 Eine pharmazeutische kolloidale Zusammensetzung enthaltend Hyaluronsäure-Biopolymere zur Behandlung von Atemwegserkrankungen

Publications (1)

Publication Number Publication Date
DE60228717D1 true DE60228717D1 (de) 2008-10-16

Family

ID=32737409

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60228717T Expired - Lifetime DE60228717D1 (de) 2002-10-10 2002-10-11 Eine pharmazeutische kolloidale Zusammensetzung enthaltend Hyaluronsäure-Biopolymere zur Behandlung von Atemwegserkrankungen

Country Status (8)

Country Link
US (1) US7060691B2 (de)
EP (1) EP1407776B1 (de)
AT (1) ATE406904T1 (de)
DE (1) DE60228717D1 (de)
DK (1) DK1407776T3 (de)
ES (1) ES2314015T3 (de)
PT (1) PT1407776E (de)
SI (1) SI1407776T1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416397D0 (en) * 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
US20080194471A1 (en) * 2005-08-10 2008-08-14 Otkrytoe Aktsyonernoe Obshchestvo "Polema" Compositions and Methods for Treating Wounds
CA2560844C (en) * 2005-09-26 2011-05-17 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
JP2009091248A (ja) * 2006-01-17 2009-04-30 Toshitsu Kagaku Kenkyusho:Kk 外傷性神経障害および／または運動機能障害の治療薬
CN101389342B (zh) 2006-12-05 2012-08-08 株式会社糖质科学研究所 用于变性关节炎的治疗剂
FR2977494B1 (fr) * 2011-07-08 2013-08-16 Ayawane Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes
ES2665254T3 (es) * 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
EP2985027B1 (de) * 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasenheilmittel enthaltend ein gemisch von hyaluronsäuren und salzlösung
EP2985019B1 (de) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasale Zusammensetzung mit antiviralen Eigenschaften
IT202000016984A1 (it) 2020-07-13 2022-01-13 Bmg Pharma S P A Composizioni igienizzanti e antiinfettive per le mucose orali
EP3991717A1 (de) * 2020-11-03 2022-05-04 SanderStrothmann GmbH Kosmetische antifaltenzusammensetzung
WO2023079072A1 (en) * 2021-11-05 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784990A (en) * 1985-01-18 1988-11-15 Bio-Technology General Corporation High molecular weight sodium hyaluronate
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
HUP9902285A3 (en) * 1996-01-11 2001-07-30 Jagotec Ag Orally administrable dosage of a form of hyaluronic acid
US6383344B1 (en) * 2000-07-19 2002-05-07 Genzyme Corporation Molecular weight reduction of polymer using irradiation treatment
CA2417867C (en) * 2000-07-31 2012-09-11 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates

Also Published As

Publication number Publication date
EP1407776B1 (de) 2008-09-03
ES2314015T3 (es) 2009-03-16
US7060691B2 (en) 2006-06-13
DK1407776T3 (da) 2009-01-19
PT1407776E (pt) 2008-12-16
US20040071740A1 (en) 2004-04-15
EP1407776A1 (de) 2004-04-14
ATE406904T1 (de) 2008-09-15
SI1407776T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
Kelen et al. Unrecognized human immunodeficiency virus infection in emergency department patients
DE60228717D1 (de) Eine pharmazeutische kolloidale Zusammensetzung enthaltend Hyaluronsäure-Biopolymere zur Behandlung von Atemwegserkrankungen
CY1115940T1 (el) Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων
ATE506948T1 (de) Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
BRPI0212455B8 (pt) composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
ATE195249T1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE602004015406D1 (de) Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen
WO2003011327A3 (en) Secretin for the treatment of asthma
Dorland The American illustrated medical dictionary
JP4366527B2 (ja) 特に眼科分野における適用のための外傷および損傷の治癒および／または修復のための治療に適したアミノ酸組成物
DE59610205D1 (de) Anwendung eines medikaments und verwendung eines stoffgemischs zur herstellung eines medikaments
Zissu et al. Nasal and pulmonary toxicity of glutaraldehyde in mice
WO2022063320A1 (zh) 一种抑制呼吸道病毒的组合物及呼吸道病毒防治方法
Lichtenberg Mercury Vapour in the Oral Cavity in Relation to the Number of Amalgam Surfaces and the Classic Symptoms of Chronic Mercury Poisoning
JP2003119491A (ja) 精神高揚用香料組成物
JP4671092B2 (ja) ウイルス感染予防および対策
RU1811407C (ru) Способ лечени бронхиальной астмы
JP2023031473A (ja) ナチュラルキラー細胞活性化剤
RU2196590C1 (ru) Средство гидросульфат углеродо-ртутный комплекс и способ лечения инфекционно-воспалительных заболеваний
Seldin Use of Nitrous Oxide-Oxygen Anesthesia in Dental Surgery.
WO2023047291A1 (en) Aerosol comprising ethanol 60 and 90% w/w and a solvent for treating a respiratory infection
JPS63107938A (ja) 皮膚疾患治療剤

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ATLAS 2002 LLC, CHERRY HILL, N.J., US

Owner name: FLOSTOCK LLC, CHERRY HILL, N.J., US

8364 No opposition during term of opposition